STEPHEN MOORE: Foreign drug price controls are a hidden tax on Americans

The article argues that foreign drug price controls in countries like Germany, France, and Japan force Americans to pay higher healthcare costs by limiting what these nations pay for medicines. It claims these policies shift global R&D costs onto the U.S. and suggests using U.S. trade law, specifically Section 301 of the 1974 Trade Act, to address the issue.